FTH
Faeth Therapeutics, Inc.
24.90$
-7.3%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
Faeth Therapeutics, Inc. (FTH) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -16 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.7 | -6.5 | -2.8 | -5.8 | -2.7 | -11 | -6.0 | -5.6 | -7.9 | -11 | -12 | -6.8 | -12 | -9.5 | -4.7 | -6.2 | -7.6 | -5.8 | -5.5 | -5.8 | -7.1 | -5.9 | -3.6 | -3.9 | -11 | -16 | -34 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.3 | 0.3 | 0.4 | 0.5 | 0.3 | 0.1 | 0.3 | – | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| 0.4 | 0.2 | 0.2 | 0.8 | 0.4 | 1.3 | 1.7 | 1.7 | 0.8 | – | 1.4 | 1.5 | 1.2 | – | 1.0 | 1.1 | 1.2 | 0.8 | 0.7 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 | 13 | 4.5 | 18 | |
| 1.6 | -2.5 | 1.4 | -1.3 | 2.0 | -4.2 | 1.7 | 2.6 | 0.1 | -0.7 | -3.5 | 4.5 | -3.2 | -1.7 | 1.0 | -0.4 | -1.4 | 0.1 | 0.6 | 0.3 | -0.9 | -1.5 | 0.5 | 0.3 | 13 | -3.5 | 11 | |
| 0.0 | 0.1 | 0.0 | 0.8 | 0.3 | 0.5 | 0.6 | 0.4 | 0.5 | 0.0 | 0.1 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 0.0 | -0.1 | -0.2 | -0.8 | -0.3 | -0.5 | -148 | -0.5 | 5.6 | 12 | 13 | 8.5 | 2.3 | 20 | 8.3 | 8.3 | 5.8 | 6.9 | 13 | -3.2 | 7.2 | 8.8 | 1.7 | 2.1 | -31 | -108 | -136 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -7.8 | -2.3 | -0.3 | 0.0 | – | – | – | 0.0 | 0.0 | 0.0 | 0.0 | -15 | -1.8 | -17 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -0.2 | -0.2 | -0.2 | -0.1 | -0.1 | 0.0 | -0.3 | |
| 1.6 | 11 | 0.6 | 8.5 | 16 | 164 | 0.0 | 0.0 | -0.1 | 0.1 | -0.1 | -0.2 | -0.3 | -7.9 | -2.5 | -0.4 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.2 | -0.1 | 186 | -1.7 | 184 | |
| 0.0 | 4.0 | -2.4 | 1.8 | 13 | 153 | -154 | -6.1 | -2.4 | 1.6 | 1.2 | 1.6 | -9.7 | 2.1 | 1.1 | 1.7 | -2.1 | 0.9 | 7.2 | -9.1 | -0.1 | 2.7 | -2.0 | -1.9 | 144 | -125 | 14 | |
| -1.7 | -6.5 | -2.8 | -6.6 | -3.0 | -11 | -6.7 | -6.0 | -8.4 | -11 | -12 | -7.1 | -12 | -9.5 | -4.7 | -6.2 | -7.7 | -5.9 | -5.5 | -5.8 | -7.1 | -5.9 | -3.6 | -3.9 | -11 | -16 | -34 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.